Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer. [electronic resource]
Producer: 20160119Description: 397-408 p. digitalISSN:- 1573-0646
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols
- Dehydroepiandrosterone Sulfate -- blood
- Disease Progression
- Disease-Free Survival
- Docetaxel
- Dose-Response Relationship, Drug
- Humans
- Imidazoles -- administration & dosage
- Male
- Middle Aged
- Naphthalenes -- administration & dosage
- Prednisone -- administration & dosage
- Prostate-Specific Antigen
- Prostatic Neoplasms, Castration-Resistant -- drug therapy
- Steroid 17-alpha-Hydroxylase -- antagonists & inhibitors
- Taxoids -- administration & dosage
- Testosterone -- blood
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.